State of New Jersey Common Pension Fund D Has $46.44 Million Stock Position in Gilead Sciences, Inc. $GILD

State of New Jersey Common Pension Fund D raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 418,848 shares of the biopharmaceutical company’s stock after purchasing an additional 1,111 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Gilead Sciences were worth $46,438,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in GILD. Brighton Jones LLC raised its stake in shares of Gilead Sciences by 20.6% in the fourth quarter. Brighton Jones LLC now owns 14,359 shares of the biopharmaceutical company’s stock valued at $1,326,000 after acquiring an additional 2,450 shares during the last quarter. Bison Wealth LLC bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $215,000. GAMMA Investing LLC raised its stake in shares of Gilead Sciences by 24.9% in the first quarter. GAMMA Investing LLC now owns 22,760 shares of the biopharmaceutical company’s stock valued at $2,550,000 after acquiring an additional 4,532 shares during the last quarter. Spire Wealth Management raised its stake in shares of Gilead Sciences by 10.6% in the first quarter. Spire Wealth Management now owns 17,212 shares of the biopharmaceutical company’s stock valued at $1,929,000 after acquiring an additional 1,652 shares during the last quarter. Finally, Golden State Wealth Management LLC raised its stake in shares of Gilead Sciences by 400.1% in the first quarter. Golden State Wealth Management LLC now owns 3,771 shares of the biopharmaceutical company’s stock valued at $423,000 after acquiring an additional 3,017 shares during the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 28th. The stock was sold at an average price of $113.63, for a total value of $1,136,300.00. Following the transaction, the chief executive officer owned 595,725 shares of the company’s stock, valued at approximately $67,692,231.75. This represents a 1.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares in the company, valued at $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 71,500 shares of company stock valued at $8,281,540 in the last three months. 0.27% of the stock is currently owned by company insiders.

Gilead Sciences Price Performance

Shares of GILD stock opened at $120.94 on Friday. Gilead Sciences, Inc. has a 12-month low of $86.08 and a 12-month high of $124.61. The firm has a market capitalization of $150.06 billion, a price-to-earnings ratio of 24.09, a price-to-earnings-growth ratio of 0.83 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The firm has a fifty day moving average of $115.47 and a 200-day moving average of $111.01.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share for the quarter, topping analysts’ consensus estimates of $1.96 by $0.05. The firm had revenue of $7.08 billion during the quarter, compared to analyst estimates of $6.95 billion. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business earned $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, equities research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Monday, September 29th. Shareholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences’s dividend payout ratio is currently 62.95%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on GILD shares. TD Cowen lifted their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the company a “buy” rating in a research note on Thursday. Wolfe Research boosted their price objective on shares of Gilead Sciences from $135.00 to $140.00 and gave the stock an “outperform” rating in a research report on Thursday. Rothschild & Co Redburn boosted their price objective on shares of Gilead Sciences from $136.00 to $143.00 and gave the stock a “buy” rating in a research report on Friday, September 12th. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 16th. Finally, Daiwa Capital Markets upgraded shares of Gilead Sciences from a “neutral” rating to an “outperform” rating and set a $128.00 price objective for the company in a research report on Tuesday, August 19th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $122.61.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.